$RUBY Doubles on Progress in Early-Stage Cancer-Drug Trial

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity.

RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events

RTX-240 Promoted Trafficking of NK and T Cells into
Tumor Microenvironment

Initial Clinical Data Provide Evidence of Broad Potential of RED PLATFORM® Across Pipeline of Cancer and Autoimmune Programs

The initial data "demonstrate that RTX-240 has the potential to generate single-agent activity in patients with solid tumors, including a cold tumor such as metastatic uveal melanoma, where other treatments have failed to induce responses in patients," Christina Coughlin, an oncologist and immunologist who is chief medical officer at Rubius Therapeutics, said in a statement.

“The encouraging safety results, including a single event of Grade 1 liver toxicity, and preliminary efficacy data for RTX-240 to date give us the potential to realize the power of immune agonists for the treatment of cancer," Coughlin added.

The ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors resulted in a 54% confirmed partial response rate in reducing the target lesions in a patient with metastatic anal cancer.

The adverse effects of the treatment included fatigue, chills, nausea, decreased appetite and arthralgia, which is pain in a joint.

Rubius is now planning a new Phase 1 study for the second half of 2021 to evaluate the combination of RTX-240 and another therapy.

It's also planning a Phase 2 expansion cohort for first-quarter 2022, according to its statement.



The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.